文献速递糖尿病

评估远程医疗对西班牙安达卢西亚地区多次胰岛素注射且HbA1c控制欠佳的1型糖尿病患者影响的随机研究:PLATEDIAN研究

Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin and Suboptimal HbA1c in Andalusia (Spain): PLATEDIAN Study.
PubMed 文献 · Diabetes Care · 2019-12-12

PLATEDIAN为多中心、随机、6个月随访、开放标签、平行对照研究,纳入多次每日胰岛素注射且HbA1c<8%的1型糖尿病患者,1:1随机分为三次面对面随访组(对照组,n=167)或其中一次面对面随访替换为使用Diabetic平台的远程医疗访视组(干预组,n=163)。主要终点为基线至第6个月HbA1c平均变化,结果显示两组相似,安全性和健康相关生活质量无显著差异。

要点

  • 在HbA1c<8%的1型糖尿病患者中,远程医疗访视与面对面访视在6个月时HbA1c变化相似。
  • 第6个月HbA1c平均变化:对照组-0.04±0.5%,干预组0.01±0.6%(P=0.4941)。
  • 两组安全终点及健康相关生活质量变化无显著差异。

核心结论

  • 在HbA1c<8%(<64 mmol/mol)的1型糖尿病患者中,使用远程医疗可提供与面对面访视相似的疗效和安全性结果。

研究设计与样本

  • PLATEDIAN(NCT03332472)为多中心、随机、6个月随访、开放标签、平行组对照研究,在多次每日胰岛素注射的1型糖尿病且代谢控制欠佳(HbA1c<8% [<64 mmol/mol])患者中进行。
  • 共评估388例患者资格,379例按1:1随机分为对照组(三次面对面访视,n=167)或干预组(将中间一次面对面访视替换为使用Diabetic平台的远程医疗访视,n=163)。

主要发现

  • 第6个月HbA1c平均变化:对照组-0.04±0.5%(-0.5±5.8 mmol/mol),干预组0.01±0.6%(0.1±6.0 mmol/mol),P=0.4941。
  • 达到HbA1c<7%(<53 mmol/mol)的患者数:对照组73例,干预组78例。
  • 6个月时安全终点未发现显著差异。
  • 首次访视至最终访视之间健康相关生活质量变化两组间无差异;关于低血糖恐惧(FH-15评分≥28),基线时观察到的统计学显著差异在6个月时保持不变(P<0.05)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the impact of a telemedicine visit using the platform Diabetic compared with a face-to-face visit on clinical outcomes, patients' health-related quality of life (HRQoL), and physicians' satisfaction in patients with type 1 diabetes. RESEARCH DESIGN AND METHODS: PLATEDIAN (Telemedicine on Metabolic Control in Type 1 Diabetes Mellitus Andalusian Patients) (NCT03332472) was a multicenter, randomized, 6-month follow-up, open-label, parallel-group controlled study performed in patients with type 1 diabetes with suboptimal metabolic control (HbA1c <8% [<64 mmol/mol]), treated with multiple daily injections. A total of 388 patients were assessed for eligibility; 379 of them were randomized 1:1 to three face-to-face visits (control cohort [CC]) (n = 167) or the replacement of an intermediate face-to-face visit by a telemedicine visit using Diabetic (intervention cohort [IC]) (n = 163). The primary efficacy end point was the mean change of HbA1c levels from baseline to month 6. Other efficacy and safety end points were mean blood glucose, glucose variability, episodes of hypoglycemia and hyperglycemia, patient-reported outcomes, and physicians' satisfaction. RESULTS: At month 6, the mean change in HbA1c levels was -0.04 ± 0.5% (-0.5 ± 5.8 mmol/mol) in the CC and 0.01 ± 0.6% (0.1 ± 6.0 mmol/mol) in the IC (P = 0.4941). The number of patients who achieved HbA1c <7% (<53 mmol/mol) was 73 and 78 in the CC and IC, respectively. Significant differences were not found regarding safety end points at 6 months. Changes in HRQoL between the first visit and final visit did not differ between cohorts, and, regarding fear of hypoglycemia (FH-15 score ≥28), statistically significant differences observed at baseline remained unchanged at 6 months (P < 0.05). CONCLUSIONS: The use of telemedicine in patients with type 1 diabetes with HbA1c <8% (<64 mmol/mol) provides similar efficacy and safety outcomes as face-to-face visits.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Ruiz de Adana MS, Alhambra-Expósito MR, Muñoz-Garach A, et al. Randomized Study to Evaluate the Impact of Telemedicine Care in Patients With Type 1 Diabetes With Multiple Doses of Insulin and Suboptimal HbA1c in Andalusia (Spain): PLATEDIAN Study. Diabetes Care. 2019. PMID: 31831473. doi:10.2337/dc19-0739

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。